Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucagon's Role in DPP-4 and SGLT2 Inhibitor Effects
NCT02792400Completed
- Sponsor
- Gentofte Hospital
- Start
- May 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of adomeglivant in type 2 diabetes mellitus (T2DM) (8 arms), sponsored by Gentofte Hospital. Primary endpoints: Difference in postprandial glucose excursions (linagliptin) and Difference in postprandial glucose excursions (empagliflozin). Started May 2016; status: completed.
02
Drugs
adomeglivant
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02792400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792400.